Identity
- Trade Name
- STAT-PACE II FDA PMA
- Generic Name
- SYSTEM, ESOPHAGEAL PACING FDA PMA
Identifiers
- PMA Number
- P840002 FDA PMA
- FDA Product Code
- LPA FDA PMA
Classification
- Device Class
- Class III FDA PMA
- Advisory Committee
- Cardiovascular FDA PMA
- FDA Decision
- APPR Approved FDA PMA
Stat-Pace II is a system for esophageal pacing, classified under the generic name 'System, Esophageal Pacing'. It is designed to deliver electrical stimulation via an esophageal electrode to regulate heart rhythm.
The device was manufactured by Cardiocommand, Inc. in Tampa, Florida, and received FDA Premarket Approval (PMA) under number P840002 on April 30, 1986. It is intended for use in cardiovascular applications as indicated by its advisory committee classification.
Frequently asked questions
What type of device is the Stat-Pace II?
The Stat-Pace II is classified as a System, Esophageal Pacing, which delivers electrical stimulation through an esophageal electrode to manage cardiac rhythm.
Who manufactured the Stat-Pace II and where were they located?
The Stat-Pace II was manufactured by Cardiocommand, Inc., located at 4920 W. Cypress St., Suite 110, Tampa, FL 33607.
When did the Stat-Pace II receive regulatory approval?
The Stat-Pace II received FDA Premarket Approval (PMA) on April 30, 1986, with PMA number P840002 and decision date recorded as 1986-04-30.
This description and any FAQs above were generated automatically from registry data and have not been verified by the manufacturer or by deviCERTS. Always check the official registry entry and the manufacturer's instructions for use before relying on them.
Authorization Coverage (1 country)
Regulatory Authorizations
FDA_PMA
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA PMA | United States | FDA_PMA | P840002 | Class III | Active |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Cardiocommand, Inc.
Sources (1)
- FDA PMA P840002 24 fields · synced Sep 18, 2026